uniQure (NASDAQ:QURE) Shares Down 3.5% – What’s Next?

Shares of uniQure (NASDAQ:QURE) traded down 3.5% on Monday . The stock traded as low as $17.21 and last traded at $17.32. 85,917 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 603,523 shares. The stock had previously closed at $17.94.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. Stifel Nicolaus boosted their price objective on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Mizuho boosted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $33.88.

uniQure Stock Up 1.7 %

The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market capitalization of $889.07 million, a P/E ratio of -3.68 and a beta of 0.41. The firm has a 50 day moving average of $10.38 and a 200-day moving average of $7.64.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. On average, equities research analysts expect that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently bought and sold shares of QURE. Vanguard Personalized Indexing Management LLC boosted its position in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. Geode Capital Management LLC boosted its position in uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after buying an additional 6,362 shares during the last quarter. American Century Companies Inc. boosted its position in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 8,642 shares during the last quarter. Finally, RTW Investments LP bought a new position in uniQure in the 3rd quarter valued at $49,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.